Summit Therapeutics stock drops more than 6% after selloff triggered by weak price action below major moving averages

Traders Union
All News
Stocks
Summit Therapeutics slides 6.39% today

Highlights

Summit Therapeutics expanded late-stage trials of Ivonescimab and secured regulatory approval for its partner Akeso in China.
A collaboration with Arcus Biosciences was initiated to broaden Summit Therapeutics clinical pipeline and international reach.
Shares of Summit Therapeutics are trading near session lows at $13.11, with bearish momentum and a projected five-day range of $11.64 to $13.98.

Expansion of Ivonescimab offsets by unrelenting negative price action

Summit Therapeutics expanded the reach of its drug Ivonescimab through the start of new late-stage clinical trials, while regulatory approval was granted to its partner Akeso in China. The company also began a collaboration with Arcus Biosciences aimed at broadening its clinical pipeline and strengthening international partnerships. These actions signal operational progress, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Summit Therapeutics under heavy technical pressure. The price trades below all major moving averages, confirming a deeply bearish trend. Recent clinical collaborations and regulatory wins did little to arrest the decline, pointing to weak investor confidence and momentum. Conflicting oscillator readings only add to uncertainty, while sellers still control the action, especially after a sharp intraday gap. "Despite operational progress, I see no reason for optimism with the stock in a clear technical downtrend — risk of further losses remains elevated."

Viktoras Karapetjanc, expert at Traders Union, highlights recent clinical trial launches and international partnerships as signals of long-term value. He believes regulatory approval and new collaborations lay critical groundwork for sustainable growth. The current selling may offer new entry points, especially if operational progress continues. "With such strong pipeline momentum, I expect the bullish structure to resume in the medium term and see further growth as the most likely scenario once short-term headwinds clear."

Sholanke Dele, market strategist, notes that persistent stock weakness reflects waning sentiment despite news flow. Global risk aversion amplifies price declines, and volatility at 4.77% warns of fragile investor confidence. Recent partnerships have not improved overall market mood. "Traders should avoid chasing short-term news — prevailing sentiment suggests more downside is likely in the near term."

Bearish bias strengthens as moving averages signal sustained downside

Summit Therapeutics is trading below its 20-, 50-, and 200-day moving averages ($13.86, $14.27, and $16.77 respectively), indicating ongoing short-, medium-, and long-term pressure from sellers. The nearest intraday resistance is at $13.61, with a floor at $12.99, and the overall MA-50 vs MA-200 alignment remains bearish. Momentum readings are mixed: MACD and Average Directional Index (ADX) signal neutral momentum, while Relative Strength Index (RSI) and Stochastic RSI both suggest selling pressure or overbought conditions. Commodity Channel Index (CCI) flashes a buy signal, but Bull/Bear Power (BBP) at 1.06 indicates buyers still dominate intraday, albeit in an overbought setup. The stock opened with a downside gap of about 2.86%, is now trading at $13.11 (down 6.39% from the previous close), and is holding near session lows with intraday volatility at 4.77%. Price action reflects damage and pressure after the open, with conflicting signals between oscillators and strong bearish daily performance.

Earlier, analysts noted that while Summit Therapeutics exhibited short- and medium-term technical strength, the longer-term trend remained under bearish pressure. The current continuation of selling below all major moving averages reinforces the downside scenario, making a break below the $11.64 support level the key risk to monitor in the sessions ahead.

Source of Data: SMMT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.